Edwards Lifesciences Corporation (EW) Q1 2023 Earnings Call Transcript

Edwards Lifesciences Corporation (NYSE:EW) Q1 2023 Earnings Conference Call April 26, 2023 5:00 PM ET

Company Participants

Mark Wilterding - SVP, IR and Treasurer

Michael Mussallem - Chairman and CEO

Scott Ullem - CFO

Bernard Zovighian - President

Larry Wood - Group President, TAVR and Surgical Structural Hear

Daveen Chopra - Global Leader of TMTT

Conference Call Participants

Larry Biegelsen - Wells Fargo

Robbie Marcus - JPMorgan

Vijay Kumar - Evercore

Joanne Wuensch - Citibank

Travis Steed - Bank of America

Danielle Antalffy - UBS

Richard Newitter - Truist

Matt Miksic - Barclays

Cecilia Furlong - Morgan Stanley

Josh Jennings - TD Cowen

Operator

Greetings, and welcome to the Edwards Lifesciences' First Quarter 2023 Earnings Results. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note that this conference is being recorded.

I will now turn the conference over to our host, Mark Wilterding, Senior Vice President, Investor Relations and Treasurer. Thank you. You may begin.

Mark Wilterding

Thank you very much, Diego, and thank you everyone for joining us. With me on today's call are Mike Mussallem, Chairman and CEO; Scott Ullem, CFO; and Bernard Zovighian, President of Edwards Lifesciences. Also joining us for the Q&A portion of the call are Larry Wood, our Group President of TAVR and Surgical Structural Heart; Daveen Chopra, our Global Leader of TMTT; and Katie Zimon our Global Leader of Critical Care.

Just after the close of regular trading, Edwards Lifesciences released first quarter 2023 financial results. During today's call, management will discuss those results included in the press release and accompanying financial schedules, and then use the remaining time for Q&A.

Please note that management will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include but aren't limited to, financial guidance and expectations for longer-term growth opportunities, regulatory approvals, clinical trials, litigation, reimbursement, competitive matters and foreign currency fluctuations. These statements speak only as of the date on which they are made, and Edwards does not undertake any obligation to update them after today.

Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important safety information may be found in the press release, our 2022 Annual Report on Form 10-K and Edwards' other SEC filings all of which are available on the company's website at edwards.com.